Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Hearts Synth Bio, Shows Venter Some Love

Over at Forbes' The Science Business blog, Matthew Herper reports on Life Technologies' $100 million investment in synthetic biology — including its recent acquisition of a majority stake in Geneart, and an equity investment in Craig Venter's Synthetic Genomics, among other transactions the company intends to make. Peter Dansky, president of molecular biology at Life Tech, told Herper that the firm intends "to replicate what we've done in molecular biology which is provide the tool kits for scientists who do this kind of work." Namely, through Geneart and Blue Heron, Life Tech "will sell access to synthetic gene sequences," as well as "the cells into which those genes are put, and the chemicals used to put the genes in the cells," according to The Science Business.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.